usz.ch Objective To assess safety up to 1 year of follow-up associated with prasugrel and clopidogrel use in a prospective cohort of patients with acute coronary syndromes (ACS). Methods Between 2009 ...

Many patients are non-responsive to clopidogrel, either secondary to drug interactions or from variations of cytochrome P450 enzymes. Prasugrel (brand name Effient, Eli Lilly and Company, Indianapolis ...

Discover comprehensive details about Prasugrel, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Those patients who exhibited less than 40% platelet inhibition (P2Y 12 ADP receptor inhibition) on clopidogrel, as determined by platelet screening analysis (VerifyNow, Accumetrics, San Diego, ...

1 National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China 2 Graduate School of Beijing University of Chinese ...

Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention are limited ...

Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention are limited ...

COMPARE CRUSH enrolled 727 patients with STEMI who were randomly assigned to a 60 mg loading dose of prasugrel (Effient, Daiichi Sankyo/Eli Lilly) as crushed or integral tablets in the ambulance.

A reduced dose of prasugrel (Effient) in older or low-weight patients with acute coronary syndrome (ACS) was tied to anti-ischemic efficacy without an excess bleed risk versus the standard dose of a ...